Letrozol Accord (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal and peripheral androgens into estrogen. By inhibiting this conversion, circulating estrogen levels drop, depriving estrogen‑dependent cancer cells of the hormone they need to proliferate.

The dose of letrozole is determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and treatment goals. Typical regimens are individualized, and patients should follow the prescriber’s specific instructions.

Letrozole is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding women, as it may be excreted in milk and affect the infant.

To order Letrozol Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letrozole, anastrozole, and exemestane are all third‑generation aromatase inhibitors. Letrozole is a non‑steroidal inhibitor with a slightly longer half‑life, offering once‑daily dosing. Anastrozole has a similar efficacy profile, while exemestane is a steroidal inhibitor that may have different side‑effect patterns, especially regarding bone health.

Letrozol Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Letrozol Accord is taken orally as a tablet. Patients should swallow the tablet whole with water, with or without food, as directed by their healthcare provider. Consistency in timing each day helps maintain stable drug levels.

Serious risks include severe liver injury, osteoporotic fractures due to reduced bone mineral density, and rare events such as pulmonary embolism or severe allergic reactions. Patients should report unexplained jaundice, persistent bone pain, sudden shortness of breath, or signs of an allergic reaction to their clinician promptly.

Letrozol Accord should not be used by premenopausal women, pregnant or breastfeeding individuals, patients with severe hepatic impairment, or anyone with known hypersensitivity to letrozole or any excipients in the tablet. Clinicians must evaluate each patient’s medical history before initiating therapy.